References
- Rosenberg SA , YangJC, RestifoNP. Cancer immunotherapy: moving beyond current vaccines. Nat. Med.10, 909–915 (2004).
- Krishnamachari Y , GearySM, LemkeCD, SalemAK. Nanoparticle delivery systems in cancer vaccines. Pharm. Res.28, 215–236 (2011).
- Hamdy S , HaddadiA, GhotbiZ, HungRW, LavasanifarA. Part I: targeted particles for cancer immunotherapy. Curr. Drug Deliv.8, 261–273 (2011).
- Bal SM , HortensiusS, DingZ, JiskootW, BouwstraJA. Co-encapsulation of antigen and Toll-like receptor ligand in cationic liposomes affects the quality of the immune response in mice after intradermal vaccination. Vaccine29, 1045–1052 (2011).
- Kazzaz J , SinghM, UgozzoliM, CheskoJ, SoenawanE, O‘HaganDT. Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency. J. Control. Release110, 566–573 (2006).
- Zhang ZP , TongchusakS, MizukamiYet al. Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery. Biomaterials 32, 3666–3678 (2011).
- Cruz LJ , TackenPJ, FokkinkRet al. Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J. Control. Release 144, 118–126 (2010).
- Zindl CL , ChaplinDD. Tumor immune evasion. Science328, 697–698 (2010).
- Beaudette TT , BachelderEM, CohenJAet al.: In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in acid-degradable microparticle vaccines. Mol. Pharm.6, 1160–1169 (2010).
- Thomann JS , HeurtaultB, WeidnerSet al. Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting. Biomaterials 32, 4574–4583 (2011).
- Mottram PL , LeongD, Crimeen-IrwinBet al. Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus. Mol. Pharm. 4, 73–84 (2007).
- Win KY , FengSS. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials26, 2713–2722 (2005).
- Kulkarni SA , FengSS. Surface functionalized nanoparticles of biodegradable polymers for targeted delivery of diagnostic and therapeutic agents across the blood–brain barrier (BBB). Nanomedicine (Lond.)6(2), 377–394 (2011).
- Carstensa MG , CampsMGM, Henriksen-LaceyMet al. Effect of vesicle size on tissue localization and immunogenicity of liposomal DNA vaccines. Vaccine 29 (29–30), 4761–4770 (2011).
- Mohanan D , SlütterB, Henriksen-LaceyMet al.: Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems. J. Control. Release147, 342–349 (2010).
- Herber DL , CaoW, NefedovaYet al. Lipid accumulation and dendritic cell dysfunction in cancer. Nat. Med. 16, 880–886 (2010).
- Nochi T , YukiY, TakahashiHet al. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat. Mater. 9, 572–578 (2010).
- DeMuth PC , Su Xf, Samuel RE, Hammond PT, Irvine DJ. Nano-layered microneedles for transcutaneous delivery of polymer nanoparticles and plasmid DNA. Adv. Mater.22, 4851–4856 (2010).